MoonLake Immunotherapeutics (MEX:MLTXN) Moat Score: 4/10 (As of Jun. 26, 2026)


MEX:MLTXN MoonLake Immunotherapeutics MEX:MLTXN
30 GF Score
Price MXN305.30
! 3 Warning Signs
View Full Analysis

What is MoonLake Immunotherapeutics Moat Score?

MoonLake Immunotherapeutics MEX:MLTXN 30 Moat Score is 4 as of Jun. 26, 2026. GuruFocus rates MEX:MLTXN with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 1,404 Biotechnology companies, MoonLake Immunotherapeutics ranks better than 88.82% on this metric.

MoonLake Immunotherapeutics has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

MoonLake Immunotherapeutics has Narrow Moat: MoonLake Immunotherapeutics has a discernible but modest moat due to its focus on innovative therapies and potential valuable patents. However, it lacks significant market share and customer loyalty, keeping its moat narrow.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes MoonLake Immunotherapeutics might have Narrow Moat - Discernible but modest moat.

MoonLake Immunotherapeutics  (MEX:MLTXN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

MoonLake Immunotherapeutics Moat Score Related Terms

MEX:MLTXN vs AVBP, BCAX, KALV: Moat Score Comparison

For the Biotechnology subindustry, MoonLake Immunotherapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MoonLake Immunotherapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MoonLake Immunotherapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where MoonLake Immunotherapeutics's Moat Score falls into.


MEX:MLTXN
30GF Score
MoonLake Immunotherapeutics MEX:MLTXN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
MoonLake Immunotherapeutics (MEX:MLTXN) has a Moat Score of 4 as of Jun. 26, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, MoonLake Immunotherapeutics ranks #157 out of 1404 companies in the Biotechnology industry, placing it in the top 11.2%.
Is MoonLake Immunotherapeutics' Moat Score too high?
MoonLake Immunotherapeutics' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. MoonLake Immunotherapeutics' value of 4 is 100% above this industry median. Based on the distribution chart, MoonLake Immunotherapeutics ranks #157 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, MoonLake Immunotherapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does MoonLake Immunotherapeutics' Moat Score compare to AVBP and BCAX?
According to the Biotechnology industry distribution chart, MoonLake Immunotherapeutics ranks #157 out of 1404 companies for Moat Score. This places MoonLake Immunotherapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. MoonLake Immunotherapeutics' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MoonLake Immunotherapeutics's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MoonLake Immunotherapeutics's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MoonLake Immunotherapeutics stock overvalued right now?
MoonLake Immunotherapeutics (MEX:MLTXN) has a current Moat Score of 4. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. MoonLake Immunotherapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For MoonLake Immunotherapeutics (MEX:MLTXN), the current Moat Score is 4 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MoonLake Immunotherapeutics Business Description

Other Exchanges MLTX:USA
Address Dorfstrasse 29, Zug, CHE, 6300
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
30GF Score

Get the complete analysis for MEX:MLTXN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN305.30
Price